Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statistical methods for active extension trials.

Zonghui Hu1, Dean Follmann

  • 1Biostatistics Research Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, 6700A Rockledge Drive, MSC 7609, Bethesda, MD, USA. huzo@niaid.nih.gov

Statistics in Medicine
|October 27, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trial.

Lancet (London, England)·2026
Same author

Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine.

NPJ vaccines·2026
Same author

Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials.

Vaccine·2026
Same author

Plasma biomarkers of immunothrombosis are independently associated with death in patients with COVID-19 on ECMO.

The Journal of infectious diseases·2026
Same author

Association between COVID-19 vaccine efficacy and epidemic force of infection.

NPJ vaccines·2026
Same author

A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples.

The Journal of infectious diseases·2025
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
Same journal

Moving From Individualized Risk-Based Prevention to Benefit-Based Prevention: Estimating Individualized Life-Years Gained From Prevention Services as a Basis for Eligibility.

Statistics in medicine·2026
Same journal

A Mixture of Distributed Lag Non-Linear Models to Account for Spatially Heterogeneous Exposure-Lag-Response Associations.

Statistics in medicine·2026
Same journal

Practical Considerations for Gaussian Process Modeling for Causal Inference in Quasi-Experimental Studies With Panel Data.

Statistics in medicine·2026
Same journal

Covariate Adjustment for Wilcoxon Two Sample Statistic and Test.

Statistics in medicine·2026
See all related articles

New methods analyze active extension clinical trials by incorporating period 2 data. These period 2 estimators offer unbiased and more efficient results when treatment effects equalize across arms after period 1.

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Pharmaceutical Research

Background:

  • Active extension trials involve sequential treatment periods.
  • Standard analysis often relies solely on period 1 data.
  • Continuous outcomes are measured at baseline and after each period.

Purpose of the Study:

  • To develop and evaluate analysis methods for active extension clinical trials.
  • To extend existing estimators (change score, ANCOVA, ML) using period 2 data.
  • To assess the bias and efficiency of period 2 estimators.

Main Methods:

  • Development of period 2 estimators incorporating data from both trial periods.
  • Comparison of period 2 estimators with traditional period 1 estimators.
  • Analysis of estimator bias and efficiency under different treatment effect scenarios.

Related Experiment Videos

Main Results:

  • Period 2 estimators are unbiased and more efficient when period 2 mean responses are equal between treatment and placebo arms.
  • Bias occurs if period 2 treatment effects differ between arms, leading to downward or upward bias.
  • Period 2 analysis can supplement, but not replace, standard period 1 analysis.

Conclusions:

  • Incorporating period 2 data enhances the efficiency of clinical trial analysis.
  • Careful consideration of assumptions regarding period 2 treatment effects is crucial for unbiased estimation.
  • Proposed methods offer a valuable extension for analyzing active extension trial designs.